SCHEMBL5232006

SCHEMBL5232006

COc1cc(N)ccc1-c1nc2c(C)nn(-c3ccccc3)c2c(=O)[nH]1

nearest known ligand 0.65

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 8/20 0.65
PDE7B Q9NP56 3/20 0.65
PDE4D Q08499 1/20 0.52
PDE5A O76074 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5232435 0.90 PDE5A (0.61) PDE7APDE7BPDE5A
SCHEMBL5233250 0.88 PDE7A (0.50) PDE7APDE7BPDE5A
SCHEMBL5229120 0.88 PDE7A (0.50) PDE7APDE7BPDE5A
SCHEMBL5234270 0.87 PDE5A (0.58) PDE7APDE7BPDE5A
SCHEMBL5231578 0.86 PDE7A (0.49) PDE7APDE7BPDE4DPDE5A
SCHEMBL5232072 0.84 PTGS2 (0.51) PDE7APDE7BPDE5A
SCHEMBL5230059 0.84 PDE7A (0.47) PDE7APDE7BPDE4DPDE5A
SCHEMBL5234570 0.84 PDE7A (0.47) PDE7APDE7BPDE5A
SCHEMBL5234499 0.84 PDE5A (0.48) PDE7APDE7BPDE5A
SCHEMBL5232040 0.83 PDE7A (0.47) PDE7APDE7BPDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1454897-B1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY ASUBIO PHARMA CO LTD (JP) 2007-10-10 EP disclosed
US-7268128-B2 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action AUSBIO PHARMA CO., LTD. (JP) 2007-09-11 US disclosed
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action OMEROS CORPORATION 2005-07-07 US disclosed
EP-1454897-A1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY Daiichi Suntory Pharma Co., Ltd. (JP) 2004-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action PDE7B, PDE3B, PDE3A PDE7A 4/4885PDE7B 1/4885PDE4D 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.